Cisplatin vs. carboplatin-based chemoradiotherapy in patients >65Â years of age with stage III non-small cell lung cancer

Carboplatin-based CRT is associated with similar long-term survival but lower rates of toxicity. These findings suggest carboplatin may be the most appropriate chemotherapeutic agent for elderly stage III patients.